1515
Annons
Scandion Oncology A/S: Scandion Oncology announces share purchase by a member of the Board of Directors

Scandion Oncology A/S, the Cancer Drug Resistance Company, today announced that a member of the Board of Directors has purchased shares in the company.

The following share purchase has been reported:

Shares purchased Total shareholding

Peter Chairman of the Board 2,500 62,065
Høngaard
Andersen

Persons under an obligation to report are defined as members of the Board of Directors and members of Executive Management.

For further information regarding Scandion Oncology, please contact:

Bo Rode Hansen, President & CEO

Phone: +45 3810 2017

E-mail: info@scandiononcology.com

Website: www.scandiononcology.com

The information was provided by the contact person above for publication on December 2, 2021, at 17.30 CET.

Scandion Oncology A/S is a clinical Phase II biotechnology company currently developing first-in-class, oral add-on drugs to existing market leading anti-cancer therapies. As add-on to standard anti-cancer therapies, it introduces an effective treatment approach for cancer, which is or has become resistant to cancer-fighting drugs. Scandion Oncology is listed on Nasdaq First North Growth Market Sweden.

Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market and can be reached at ca@vhcorp.seor +46 (0) 40 200 250.

Source: Cision
Tillbaka

Det verkar som att du använder en annonsblockerare

Om du är prenumerant behöver du logga in för att fortsätta. Vill bli prenumerant kan du läsa Di Digitalt för 197 kr inkl. moms de första 3 månaderna.

  • Full tillgång till di.se med nyheter och analyser

  • Tillgång till över 1100 aktiekurser i realtid

  • Dagens industri som e-tidning redan kvällen innan

  • Innehållet i alla Di:s appar, tjänster och nyhetsbrev

3 månader för
197 kr
Spara 1000 kr

Prenumerera

Redan prenumerant?